Novo Nordisk (NVO) said Monday it has signed a partnership with Amazon.com's (AMZN) Amazon Web Services to advance drug discovery for serious chronic conditions and upgrade its operations through agentic artificial intelligence and cloud technologies.
Financial terms were not disclosed.
Under the partnership, Novo Nordisk will use Amazon Bio Discovery and Amazon Bedrock to identify drug targets, accelerate the design of new therapies, and connect genomic, imaging, and clinical data, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments